CA2434641A1 - Preparations de microemulsion chimiotherapeutique de paclitaxel presentant une meilleure biodisponibilite orale - Google Patents

Preparations de microemulsion chimiotherapeutique de paclitaxel presentant une meilleure biodisponibilite orale Download PDF

Info

Publication number
CA2434641A1
CA2434641A1 CA002434641A CA2434641A CA2434641A1 CA 2434641 A1 CA2434641 A1 CA 2434641A1 CA 002434641 A CA002434641 A CA 002434641A CA 2434641 A CA2434641 A CA 2434641A CA 2434641 A1 CA2434641 A1 CA 2434641A1
Authority
CA
Canada
Prior art keywords
composition
paclitaxel
cellulosic polymer
group
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002434641A
Other languages
English (en)
Inventor
Ping Gao
Walter Morozowich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2434641A1 publication Critical patent/CA2434641A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des préparations pharmaceutiques adaptées pour l'administration orale contenant du paclitaxel, un solvant, un surfactant, un polymère cellulosique substitué et éventuellement mais de préférence un inhibiteur P-glycoprotéine. Cette préparation peut également contenir un diglycéride ou un mélange de diglycéride et de monoglycéride. La préparation produit une microémulsion de paclitaxel sursaturée lors du contact avec l'eau, ce qui procure une meilleure biodisponibilité de paclitaxel.
CA002434641A 2001-01-18 2002-01-14 Preparations de microemulsion chimiotherapeutique de paclitaxel presentant une meilleure biodisponibilite orale Abandoned CA2434641A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26255501P 2001-01-18 2001-01-18
US60/262,555 2001-01-18
PCT/US2002/000497 WO2002064132A2 (fr) 2001-01-18 2002-01-14 Preparations de microemulsion chimiotherapeutique de paclitaxel presentant une meilleure biodisponibilite orale

Publications (1)

Publication Number Publication Date
CA2434641A1 true CA2434641A1 (fr) 2002-08-22

Family

ID=22998000

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002434641A Abandoned CA2434641A1 (fr) 2001-01-18 2002-01-14 Preparations de microemulsion chimiotherapeutique de paclitaxel presentant une meilleure biodisponibilite orale

Country Status (9)

Country Link
EP (1) EP1365759A2 (fr)
JP (1) JP2004520398A (fr)
AR (1) AR032642A1 (fr)
CA (1) CA2434641A1 (fr)
MX (1) MXPA03006404A (fr)
NZ (1) NZ539046A (fr)
PE (1) PE20020833A1 (fr)
WO (1) WO2002064132A2 (fr)
ZA (1) ZA200305086B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
FR2838349B1 (fr) * 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
EP1498120A1 (fr) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Formulation semi-solide pour l'administration orale du taxol
EP1498143A1 (fr) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Formulations auto-émulsifiantes et auto-microémulsifiantes pour l'administration orale de taxoides
US20050123602A1 (en) * 2003-09-25 2005-06-09 Michaelis Arthur F. Rifalazil formulations
EP1904052A4 (fr) * 2005-06-17 2008-12-10 Hospira Australia Pty Ltd Compositions pharmaceutiques liquides de docétaxel
US20100168410A1 (en) * 2006-10-27 2010-07-01 Pfizer Products Inc. Hydroxypropyl Methyl Cellulose Hard Capsules and Process of Manufacture
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
US9345683B2 (en) * 2010-11-08 2016-05-24 Cadila Pharmaceuticals Limited Pharmaceutical composition of taxoids
CN103110581B (zh) * 2013-02-26 2015-07-22 西南大学 一种紫杉醇微乳药物组合物及其制备方法
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
CN108136030B (zh) * 2015-07-30 2021-01-26 大化制药株式会社 含有高浓度紫杉烷的用于口服给药的药物组合物
CN107028931A (zh) * 2016-02-04 2017-08-11 上海宣泰医药科技有限公司 一种紫杉醇药物组合物及其药物制剂、制备方法和用途
EP3701943A1 (fr) * 2019-02-26 2020-09-02 CAPNOMED GmbH Administration retardée de médicaments anticancer
WO2023220109A1 (fr) * 2022-05-11 2023-11-16 Eli Lilly And Company Compositions pharmaceutiques à base de glp1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1998013359A1 (fr) * 1996-09-24 1998-04-02 Marigen S.A. Ultramicroemulsions constituees de concentres pouvant etre disperses de façon spontanne, renfermant des esters de composes de baccatine-iii a effet antitumoral et antiviral
CH688504A5 (de) * 1997-03-26 1997-10-31 Marigen Sa Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit antitumoral wirksamem Taxol und mit Taxol-analogen Verbindungen.
JP2002500667A (ja) * 1997-05-27 2002-01-08 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物
AU3574097A (en) * 1997-06-20 1999-01-04 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
IL143580A0 (en) * 1998-12-11 2002-04-21 Pharmasolutions Inc Pharmaceutical compositions containing lipophilic drugs and methods for the preparation thereof
CA2371836C (fr) * 1999-05-27 2006-01-31 Acusphere, Inc. Matrices medicamenteuses poreuses et procedes de fabrication associes
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
WO2002043765A2 (fr) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Formulations pharmaceutiques contenant du paclitaxel, ses derives et ses sels pharmaceutiquement acceptables

Also Published As

Publication number Publication date
PE20020833A1 (es) 2002-09-19
MXPA03006404A (es) 2004-12-02
ZA200305086B (en) 2004-06-30
NZ539046A (en) 2006-11-30
EP1365759A2 (fr) 2003-12-03
AR032642A1 (es) 2003-11-19
WO2002064132A2 (fr) 2002-08-22
WO2002064132A3 (fr) 2003-05-30
JP2004520398A (ja) 2004-07-08

Similar Documents

Publication Publication Date Title
US7115565B2 (en) Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
JP3276368B2 (ja) 親油性薬剤用の２相放出配合物
US6306434B1 (en) Pharmaceutical composition comprising cyclosporin solid-state microemulsion
CA2434641A1 (fr) Preparations de microemulsion chimiotherapeutique de paclitaxel presentant une meilleure biodisponibilite orale
ES2326783T3 (es) Composiciones de n-benzoilestaurosporina espontaneamente dispersables.
EA029996B1 (ru) Капсулярная лекарственная форма, содержащая суспензионную композицию производного индолинона
BRPI0809563A2 (pt) Formas de dosagem modificadas de tacrolimus
US20210346302A1 (en) Pharmaceutical Formulation
JPH0451528B2 (fr)
CN112168781B (zh) 他克莫司的自微乳组合物及其制备方法
WO1997035587A1 (fr) Compositions contenant un inhibiteur de la protease du vih tel que le vx 478 et un compose hydrosoluble de vitamine e tel que la vitamine e-tpgs
JP3585245B2 (ja) セルトラリンのゼラチンカプセル封入溶液剤形
AU2002249926A1 (en) Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
AU2007262493A1 (en) Pharmaceutical composition for oral administration
Gao et al. Design and development of supersaturatable self-emulsifying drug delivery systems for enhancing the gastrointestinal absorption of poorly soluble drugs
US20230310465A1 (en) Nano lipid carrier system for improving permeation of active ingredients
JP2002540158A (ja) レトロウイルスプロテアーゼインヒビター用医薬エマルジョン
AU2922800A (en) Pharmaceutical compositions for oral administration comprising a benzamide and at least an absorption promoter
KR100535228B1 (ko) 란소프라졸함유 경질캅셀제의 제조방법
CN117771249A (zh) 拉帕替尼自微乳组合物及其制备方法
BR102018016507A2 (pt) Composição líquida de liberação prolongada de guaifenesina
JP2010513351A (ja) 酸を含むゼラチンカプセル剤
EP0906107A1 (fr) Compositions contenant un inhibiteur de la protease du vih tel que le vx 478 et un compose hydrosoluble de vitamine e tel que la vitamine e-tpgs
MXPA99012099A (en) Gelatine encapsulated solution dosage forms of sertraline

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20080114